ACP
TRVI icon

Acuta Capital Partners’s Trevi Therapeutics TRVI Stock Holding History

Acuta Capital Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-493,735
Closed -$2.7M – 33
2025
Q2 		$2.7M Sell
493,735
-292,226
-37% -$1.82M 3.77% 11
2025
Q1 		$4.94M Buy
785,961
+14,003
+2% +$66.8K 5.73% 6
2024
Q4 		$3.18M Buy
771,958
+481,458
+166% +$1.54M 3.2% 11
2024
Q3 		$970K Buy
290,500
+30,500
+12% +$90.7K 0.79% 26
2024
Q2 		$775K Buy
+260,000
New +$722K 0.65% 24
2022
Q4 		– Sell
-36,302
Closed -$56K – 47
2022
Q3 		$56K Buy
36,302
+1,302
+4% +$4.27K 0.02% 45
2022
Q2 		$98K Buy
+35,000
New +$86K 0.05% 41

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Acuta Capital Partners's TRVI Position: Q3 2025 in Review

Acuta Capital Partners sold out of Trevi Therapeutics (TRVI) in Q3 2025, closing a stake of 493,735 shares — an estimated $2.7M sold.

Acuta Capital Partners first reported a position in TRVI in Q2 2022 and held it in 7 quarters. The position peaked at $4.94M in Q1 2025. 164 funds tracked by Wall St. Rank hold TRVI as of Q3 2025.

  • Acuta Capital Partners reported no remaining Trevi Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 493,735 Trevi Therapeutics shares in Q3 2025, an estimated $2.7M.
  • Acuta Capital Partners first reported a position in Trevi Therapeutics in Q2 2022 and held it in 7 quarters.
  • Acuta Capital Partners's Trevi Therapeutics position peaked at $4.94M in Q1 2025.
  • 164 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q3 2025.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.